Progress and opportunities in measuring the burden of Chronic Kidney Disease by Priya Vart, Hiddo J.L. Heerspink

Get full text

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis by K. Melissa Hallow, K. Melissa Hallow, Peter J. Greasley, Hiddo J. L. Heerspink, Hiddo J. L. Heerspink, Hongtao Yu

Get full text

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trial... by Willem Collier, Benjamin Haaland, Lesley A. Inker, Hiddo J.L. Heerspink, Tom Greene

Get full text

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives by Frederik F. Kreiner, Philip Andreas Schytz, Hiddo J. L. Heerspink, Bernt Johan von Scholten, Thomas Idorn

Get full text

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020 by Elisabeth Bakker, Viktoriia Starokozhko, Jet W. M. Kraaijvanger, Hiddo J. L. Heerspink, Peter G. M. Mol

Get full text

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN... by Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Søren Rasmussen, Linda G. Mellbin

Get full text

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure by Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink

Get full text

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial by Taha Sen, Jingwei Li, Brendon L. Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Wayne Shaw, William Canovatchel, Michael K. Hansen, Hiddo J. L. Heerspink

Get full text

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial by Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J. L. Heerspink

Get full text

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial by Reza Mohebi, Yuxi Liu, Michael K. Hansen, Yshai Yavin, Naveed Sattar, Carol A. Pollock, Javed Butler, Meg Jardine, Serge Masson, Hiddo J. L. Heerspink, James L. Januzzi Jr

Get full text

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... by Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

Get full text

Protocol for a randomized study assessing the feasibility of home-based albuminuria screening among the general population: The THOMAS study. by Dominique van Mil, Lyanne M Kieneker, Birgitte Evers-Roeten, Marc H M Thelen, Hanne de Vries, Marc H Hemmelder, Annemiek Dorgelo, Ronald W van Etten, Hiddo J L Heerspink, Ron T Gansevoort

Get full text

Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with E... by Melanie Reijrink, Stefanie A. De Boer, Anniek M. Van Roon, Riemer H. J. A. Slart, Bernadette O. Fernandez, Martin Feelisch, Hiddo J. L. Heerspink, Harry Van Goor, Jan-Luuk Hillebrands, Douwe J. Mulder

Get full text

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial by Glenn M. Chertow, Ricardo Correa‐Rotter, Priya Vart, Niels Jongs, John J. V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Get full text

Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney diseaseResearch in context by Xavier G.L.V. Pouwels, Dominique van Mil, Lyanne M. Kieneker, Cornelis Boersma, Ronald W. van Etten, Birgitte Evers-Roeten, Hiddo J.L. Heerspink, Marc H. Hemmelder, Marloes L.P. Langelaan, Marc H.M. Thelen, Ron T. Gansevoort, Hendrik Koffijberg

Get full text

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study by Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J.L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernán Trimarchi, Vlado Perkovic

Get full text

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials by Robert A. Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George Bakris, Tara I. Chang, Hiddo J. L. Heerspink, Meg J. Jardine, Kenneth W. Mahaffey, Bruce Neal, Carol Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L. Neuen

Get full text

Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial by Tamara K. Young, Nigel D. Toussaint, Gian Luca Di Tanna, Clare Arnott, Carinna Hockham, Amy Kang, Aletta E. Schutte, Vlado Perkovic, Kenneth W. Mahaffey, Rajiv Agarwal, George L. Bakris, David M. Charytan, Hiddo J. L. Heerspink, Adeera Levin, Carol Pollock, David C. Wheeler, Hong Zhang, Meg J. Jardine

Get full text

Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente... by Jelle M. Beernink, Milou M. Oosterwijk, Job F. M. van Boven, Job F. M. van Boven, Hiddo J. L. Heerspink, Stephan J. L. Bakker, Stephan J. L. Bakker, Gerjan Navis, Roos M. Nijboer, Christina M. Gant, Christina M. Gant, Heleen Haverkate, Willemien J. Kruik-Kollöffel, Gozewijn D. Laverman, Gozewijn D. Laverman

Get full text

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial by Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine

Get full text